**7.3 Ocular surface advance treatment**

Ciclosporine % (Restasis) [49]:

Cochrane: studies support the topical CsA may increase the number of conjunctival goblet cells- FDA Approved


Lifetigrast 5% (Xidra) [50]:


Serum tears: [51].

